Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis
Top Cited Papers
Open Access
- 27 February 2017
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (5) , 774-790
Abstract
Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence‐based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.Keywords
This publication has 98 references indexed in Scilit:
- Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational studyBritish Journal of Dermatology, 2013
- The association between psoriasis and obesity: a systematic review and meta-analysis of observational studiesNutrition & Diabetes, 2012
- Screening for Mycobacterium tuberculosis Using an Interferon-Gamma Release AssayJournal of Public Health Management & Practice, 2012
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trialsJournal of the American Academy of Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Bone changes in children on long-term treatment with etretinateJournal of the American Academy of Dermatology, 1987